申请人:ELI LILLY AND COMPANY
公开号:EP0997460A1
公开(公告)日:2000-05-03
This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.
wherein
E is CRe or N in which Re is hydrogen, methyl, methoxy or halo;
R1 is hydrogen or methyl;
R2 is R2a or R2b in which
R2a is -X2-(CH2)n-Rf in which X2 is a direct bond, methylene or O; n is 1, 2 or 3; and Rf is 5-tetrazolyl, carboxy, [(1-4C)alkoxy]carbonyl or hydroxymethyl;
R2b is -X2-(CH2)m-NRaRb in which X2 is a direct bond, methylene or O; m is 1, 2 or 3; provided that when m is 1, then X2 is a direct bond; and Ra and Rb are independently hydrogen or (1-3C)alkyl or the group NRaRb is pyrrolidino, piperidino or morpholino;
R3 is -X3-(CH2)s-NRsRt in which X3 is a direct bond, methylene or O; s is 1 or 2; provided that when s is 1, then X3 is a direct bond; and Rs and Rt are independently hydrogen or (1-3C)alkyl or the group NRsRt is pyrrolidino, piperidino or morpholino; and
R6 is hydrogen, hydroxy or methoxy.
本申请涉及本文定义的新型式 I 化合物(及其药学上可接受的盐)、其制备工艺和中间体、包含新型式 I 化合物的药物制剂,以及式 I 化合物作为凝血酶抑制剂的用途。
其中
E 是 CRe 或 N,其中 Re 是氢、甲基、甲氧基或卤素;
R1 是氢或甲基
R2 是 R2a 或 R2b,其中
R2a 是-X2-(CH2)n-Rf,其中 X2 是直接键、亚甲基或 O;n 是 1、2 或 3;Rf 是 5-四唑基、羧基、[(1-4C)烷氧基]羰基或羟甲基;
R2b 是-X2-(CH2)m-NRaRb,其中 X2 是直接键、亚甲基或 O;m 是 1、2 或 3;但当 m 是 1 时,X2 是直接键;Ra 和 Rb 独立地是氢或 (1-3C)烷基或基团 NRaRb 是吡咯烷基、哌啶基或吗啉基;
R3 是-X3-(CH2)s-NRsRt,其中 X3 是直接键、亚甲基或 O;s 是 1 或 2;条件是当 s 为 1 时,X3 是直接键;Rs 和 Rt 独立地是氢或 (1-3C)烷基或基团 NRsRt 是吡咯烷基、哌啶基或吗啉基;以及
R6 是氢、羟基或甲氧基。